Equity Profile

AUPH

Aurinia Pharmaceuticals Inc.

Health CareBiotechnology$2.0B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for kidney diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses and revenues.

$0.24

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$80M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for kidney diseases. With a market cap of $2 billion, it plays a significant role in the health care sector, particularly in addressing unmet medical needs in autoimmune diseases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

In Q1 2026, Aurinia reported an EPS of $0.25, significantly beating estimates by 38.89%. However, the stock fell 6.80% the following day, indicating market skepticism despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect Aurinia to report solid earnings this quarter, with a consensus EPS of $0.24 and revenue of $80 million. The market is closely watching for any signs of growth or challenges in its product pipeline.

Bull Case

If Aurinia exceeds expectations, it could signal strong demand for its therapies and confidence in future growth, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings or provides weak guidance, it could raise concerns about its market position and lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$0.24

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses and revenues.

Revenue

$80M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Aurinia's revenue meet or exceed the $80 million consensus estimate?

Revenue performance is crucial for assessing the company's growth trajectory and market acceptance of its products.

What guidance will management provide for future quarters?

Future guidance will indicate management's confidence in sustaining growth and could heavily influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Aurinia's potential for revenue growth, as recent product developments could drive higher-than-expected sales.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders anticipate volatility that may not align with conservative revenue expectations.

Key Risk

If revenue comes in significantly above $80 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Aurinia can maintain its growth momentum or if it faces significant challenges.

Bull Confirmed If

Achieving an EPS of $0.29 or higher would confirm strong operational performance.

Bear Confirmed If

Reporting an EPS below $0.21 would raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that traders expect volatility.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests the stock could rise by an average of +1.03%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around -1.44%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on customer feedback and adoption rates for existing therapies.
4Guidance on future earnings and revenue projections.
5Insights into any potential partnerships or collaborations that could enhance growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

DYNBMO

Dyne Therapeutics, Inc.

PreviewView

Jul27

ARLPBMO

Company Snapshot

Aurinia Pharmaceuticals Inc. is a biotechnology company focused on developing innovative therapies for kidney diseases....

Key Metrics to Watch

EPS

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses and revenues.

$0.24

Revenue

Revenue figures will provide insight into the company's sales performance and market demand for its products.

$80M

Wall Street expectations, options signals, track record, and call prep available with Pro.

AUPH Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+142.91%

Avg Stock Reaction

+0.41%

Last Quarter Recap

In Q1 2026, Aurinia reported an EPS of $0.25, significantly beating estimates by 38.89%. However, the stock fell 6.80% the following day, indicating market skepticism despite the strong earnings.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Aurinia exceeds expectations, it could signal strong demand for its therapies and confidence in future growth, potentially driving the stock higher.

Bear Case

Conversely, if the company misses earnings or provides weak guidance, it could raise concerns about its market position and lead to a significant drop in stock price.

Key Metrics to Watch

EPS

$0.24

Earnings per share is a key indicator of profitability and will show how well the company is managing its expenses and revenues.

Revenue

$80M

Revenue figures will provide insight into the company's sales performance and market demand for its products.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will Aurinia's revenue meet or exceed the $80 million consensus estimate?

Revenue performance is crucial for assessing the company's growth trajectory and market acceptance of its products.

What guidance will management provide for future quarters?

Future guidance will indicate management's confidence in sustaining growth and could heavily influence investor sentiment.

Edge

What the Street Is Missing

Why consensus could be wrong

The consensus may underestimate Aurinia's potential for revenue growth, as recent product developments could drive higher-than-expected sales.

Supporting Evidence

The company has a strong track record of beating EPS estimates, with a 75% beat rate over the last eight quarters.

Options pricing suggests a significant move, indicating that traders anticipate volatility that may not align with conservative revenue expectations.

Key Risk

If revenue comes in significantly above $80 million, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Aurinia can maintain its growth momentum or if it faces significant challenges.

Bull Confirmed If

Achieving an EPS of $0.29 or higher would confirm strong operational performance.

Bear Confirmed If

Reporting an EPS below $0.21 would raise concerns about the company's profitability.

Pre-Earnings Positioning

Options Market

Implied Move

±23.81%

Historical Avg

±5.3%

Pricing rich

The options market is pricing in a significant move around the earnings announcement, suggesting that traders expect volatility.

Options are pricing ±23.8% while AUPH has averaged ±5.3% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.3%

30d HV

38.5%

Calls (23K)P/C Ratio: 0.02Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Aurinia beats expectations, history suggests the stock could rise by an average of +1.03%, confirming positive market sentiment.

In-Line / Cautious

If results are in line with expectations, the stock may experience muted movement as investors await further guidance.

Miss

A miss could lead to a decline of around -1.44%, reflecting investor disappointment and concerns about future performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on product pipeline developments and their expected impact on revenue.
2Management's commentary on market conditions and competitive landscape.
3Details on customer feedback and adoption rates for existing therapies.
4Guidance on future earnings and revenue projections.
5Insights into any potential partnerships or collaborations that could enhance growth.